Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
Holding HK:2315?
Track your performance easily
2315 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$5.60 - HK$10.70
Previous CloseN/A
Volume49.50K
Average Volume (3M)N/A
Market Cap
HK$3.01B
Enterprise ValueHK$3.32B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Apr 01, 2025EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding110,781,920
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H News
PremiumCompany Announcements
Biocytogen Pharmaceuticals Reinforces Growth with Share Award Scheme
PremiumCompany Announcements
Biocytogen Secures Licensing Deal with IDEAYA
PremiumCompany Announcements
Biocytogen Reveals Strong Half-Year Financials
PremiumCompany Announcements
Biocytogen Pharmaceuticals Announces Upcoming Board MeetingPremiumCompany Announcements
Biocytogen Pharmaceuticals Forecasts Growth
PremiumCompany Announcements
Biocytogen Inks Major Deal with IDEAYA BiosciencesPremiumCompany Announcements
Biocytogen and SOTIO Forge Cancer Treatment Alliance
PremiumCompany Announcements
Biocytogen Secures U.S. Patent for Antibody Platform2315 FAQ
What was Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price range in the past 12 months?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H lowest stock price was HK$5.60 and its highest was HK$10.70 in the past 12 months.
What is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s market cap?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s market cap is HK$3.01B.
When is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s upcoming earnings report date?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s upcoming earnings report date is Apr 01, 2025 which is in 71 days.
How were Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s earnings last quarter?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H released its earnings results on Aug 28, 2024. The company reported -HK$0.138 earnings per share for the quarter, missing the consensus estimate of -HK$0.128 by -HK$0.011.
Is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H overvalued?
According to Wall Street analysts Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price is currently Overvalued.
Does Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H pay dividends?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H does not currently pay dividends.
What is Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s EPS estimate?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s EPS estimate is 0.01.
How many shares outstanding does Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H have?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H has 110,781,920 shares outstanding.
What happened to Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H’s price movement after its last earnings report?
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H reported an EPS of -HK$0.138 in its last earnings report, missing expectations of -HK$0.128. Following the earnings report the stock price went down -0.159%.
Which hedge fund is a major shareholder of Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2315
---
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-24.70%
12-Months-Change
Fundamentals
Return on Equity
-28.79%
Trailing 12-Months
Asset Growth
-10.87%
Trailing 12-Months
Technical Analysis
Akeso, Inc.
―
TOT BIOPHARM International Co. Ltd.
―
Vanov Holdings Company Limited
―
Lai Si Enterprise Holding Ltd.
―
---